STUDY DESIGN AND METHODS:
In this prospective nonrandomized study, 36 patients with non-Hodgkin lymphoma received FIL, 67 received PEG, and 16 patients received LIPEG as a cytokine after chemotherapy. We analyzed the mobilization and collection of CD34 + cells, cellular composition of blood grafts, and hematologic recovery after auto-SCT according to the type of G-CSF used. /kg, p = 0.105 or PEG 1.8 × 10 6 /kg, p = 0.012). Also, the costs associated with G-CSF mobilization and apheresis were lower in the LIPEG group. The graft composition was comparable except for the higher infused CD34 + cell counts in the LIPEG group. The engraftment kinetics were significantly slower in the FIL group.
RESULTS:
CONCLUSION: LIPEG appears to be more efficient compared with PEG after chemotherapy to mobilize CD34 + cells for auto-SCT demonstrated as fewer sessions of aphereses needed as well as 2.8-fold CD34 + cell yields on the first apheresis day. Early hematologic recovery was more rapid in the LIPEG group. Thus further studies on LIPEG in the mobilization setting are warranted.
was the first recombinant G-CSF approved 4 for mobilization purposes by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) followed by biosimilar formulations of FIL almost 20 years later. Pegfilgrastim (PEG), a pegylated derivative of FIL, was launched about a decade ago to shorten neutropenia after chemotherapy. 5, 6 This cumulative experience has became available on the efficacy and practicability of the off-label use of PEG as a single dose after chemotherapy to mobilize CD34 + cells for transplant purposes. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Lipegfilgrastim (LIPEG) is a conjugate of FIL with a single polyethylene glycol molecule. The EMA approved LIPEG in 2013 for various malignancies to reduce the length and severity of neutropenia following chemotherapy. 18 In this context, limited data are available on the administration of LIPEG after auto-SCT. [18] [19] [20] [21] Currently no published experience of LIPEG to mobilize blood grafts for transplant purposes is available.
To date, comparable studies of various G-CSFs including filgrastim biosimilars in hematopoietic progenitor cell mobilization regarding blood graft cellular composition, engraftment, and survival are scarce. This prospective multicenter analysis, part of the nonrandomized Graft and Outcome in Autologous Transplantation (GOA) study, compared the three G-CSFs just described regarding mobilization efficacy of CD34 + cells, blood graft cellular composition, as well as posttransplant hematologic recovery in NHL patients.
PATIENTS AND METHODS

Patients
Between January 2013 and December 2016, altogether 119 NHL patients from three university hospital districts (Kuopio, Oulu, and Tampere) received chemotherapy plus G-CSF to mobilize blood grafts. After the mobilization at the point of apheresis, all patients gave written informed consent for participation in the observational and nonrandomized GOA study that was designed to assess blood graft cellular composition, hematological recovery after transplantation, and clinical outcome after different methods used in the mobilization. FIL was used in Oulu and Tampere University Hospitals for mobilizing purposes whereas Kuopio University district utilized PEG as a G-CSF, and from October 2015 onwards LIPEG was used according to the basic assortment of medicinal products chosen in the hospital area. The classification of patients according to the G-CSFs used in the mobilization was made at the time of analysis. Table 1 lists the characteristics of the patients as well as the mobilization chemotherapy regimens used.
Mobilization and collection of stem cells
The mobilization chemotherapy as well as the type of G-CSF was administered according to the institutional standards of care. Thirty-six patients (30%) received filgrastim (FIL group), 67 patients (56%) received pegfilgrastim (PEG group), and 16 patients (13%) received lipegfilgrastim (LIPEG group) as a G-CSF after chemotherapy.
Subcutaneous G-CSF was started 24 hours after the last dose of chemotherapy. FIL (10 μg/kg) was continued daily until apheresis was completed. PEG was used as a 6-mg single dose ( At Kuopio University Hospital the collections were performed initially using Spectra-Auto (Terumo BCT) peripheral blood stem cell apheresis machine (eight patients) and since April 2013 the Spectra Optia (Terumo BCT) mononuclear cell program. The Spectra Optia leukapheresis system was used at both Oulu University Hospital and Tampere University Hospital. The blood volume circulated daily was 2 to 2.5 times the estimated total blood volume.
The number of CD34 + cells in the apheresis product (LA-CD34 + ) was measured after every collection by flow cytometry using an ISHAGE protocol. 22 Dimethylsulfoxide (final concentration of 10%) was used to protect the cells during cryopreservation. The apheresis products were frozen in liquid nitrogen with a controlled-rate freezing program and stored in a liquid nitrogen freezer (−170 C).
Graft analysis
Two 0.5-mL specimens were taken after each apheresis for future analysis and preserved as the grafts. Eleven patients (10%) with primary central nervous system lymphoma received the combination of thiotepa (5 mg/kg twice/day from Day −5 to Day −4) and carmustine (400 mg/m 2 on Day −6) followed by infusion of the total harvested graft on Day 0. Filgrastim 5 μg/kg was administered for 26 patients (24%) from Day +1 after the graft infusion until neutrophil recovery, pegfilgrastim 6 mg was given for 51 patients (46%), and lipegfilgrastim 6 mg for 33 patients (30%) on the first day after the graft infusion. The definition of engraftment was composed of an absolute neutrophil count of more than 0.5 × 10 9 /L and platelet count of more than 20 × 10 9 /L without platelet transfusions for 3 consecutive days according to CIBMTR instructions. 23 The hematopoietic graft function was evaluated by enumeration of complete blood counts at Day + 15 and at +1, +3, +6, and + 12 months after the graft infusion. 
Statistical methods
Analyses were performed within all patients and between the groups. All calculations and statistical analyses were carried out with IBM SPSS Statistics v.24 software. Continuous numerical variables were described using medians with ranges. Descriptive statistics were presented in frequencies and percentages if they concerned categorical variables.
Comparisons of continuous variables between the three cohorts were performed using the Kruskal-Wallis test and one-way analysis of variance when appropriate. Assumption of normality was analyzed by the Shapiro-Wilk test. Comparisons of continuous variables between the two cohorts were tested by utilizing the Mann-Whitney U-test or t test, and comparisons of nominal data were performed using the Pearson χ 2 or Fisher exact tests. Pairwise comparisons were corrected by Bonferroni adjustments. A two-tailed p value <0.05 was considered significant.
Ethics
The study was conducted according to the Declaration of Helsinki. The observational prospective GOA study was approved by the Research Ethics Committee of the North Savo Hospital District (13/2012). Written informed consent was obtained from all patients.
RESULTS
Mobilization efficiency and collection of blood grafts
A total of 110 patients achieved the minimum collection target of at least 2 × 10 6 CD34 + cells/kg (Table 2) , and two patients with lower collection yields were also accepted for transplantation (1.6 × 10 6 and 1. Table 2 ). The relative median cost of G-CSF mobilization and apheresis according to the G-CSF group is presented in Table 3 . 24 The total cost including plerixafor appeared to be lower in the LIPEG group (p < 0.001).
Graft cellular composition of blood grafts
The + cells as well as the number of various lymphocyte subsets was comparable between these three groups.
The cellular composition of cryopreserved grafts according to the G-CSF type used is presented in Table 4 .
Hematological recovery after auto-SCT
The neutrophil engraftment took place in a median of Overall, 94 patients (84%) had febrile neutropenia, and a minority of those patients (21 patients [22%]) had bacteremia during auto-SCT. Statistically significant differences in the prevalence of febrile neutropenia or blood culture positivity between the groups were observed (FIL 71% vs. PEG 92% vs. LIPEG 86%, p = 0.023), although the incidence of bacteremia was comparable between these three groups (p = 0.502), respectively. The hematologic recovery was superior in the LIPEG group in terms of WBCs as well as neutrophil counts at Day 15 after auto-SCT compared with the FIL (p < 0.001 and p < 0.001) or the PEG groups (p = 0.063 and p = 0.087). Figure 1 presents the hematologic recovery after auto-SCT according to the G-CSF type used in mobilization with the exception of comparable lymphocyte recovery. G-CSFs are necessary for the adequate mobilization of blood progenitor cells for transplant purposes. Historically, filgrastim has been used as a cytokine in mobilization settings. Encouraging data on PEG regarding efficacy and usefulness in the progenitor cell mobilization are available, but published data on LIPEG in this context are lacking. To the best of our knowledge, this is the first prospective, although nonrandomized, study to compare FIL, PEG, and LIPEG added to chemotherapy to mobilize blood grafts for auto-SCT and also includes analysis of graft cellular composition as well as posttransplant recovery. The main finding was that LIPEG resulted in higher CD34 + yields at the first apheresis as well as fewer apheresis days compared with the use of either FIL or PEG. The graft cellular composition was comparable between the G-CSF groups except for higher CD34 + cell counts in the LIPEG group. Neutrophil engraftment after transplantation was more rapid in the LIPEG and PEG groups compared with the FIL group, and platelet engraftment was most rapid in the LIPEG group. A key factor for a successful hematopoietic as well as immunologic recovery after auto-SCT is the strategy to collect adequate grafts. [25] [26] [27] Currently blood grafts are preferentially (>98%) used in an autologous setting. 3, 28 The development of recombinant G-CSFs for the mobilization of progenitor cells was one of the milestones in the history of auto-SCT. 29, 30 A short-life FIL was approved in 1991 by the FDA. 31 More recently, biosimilar FIL preparations have also become available. [32] [33] [34] A recent randomized study as well as a meta-analysis and a review concluded that biosimilar FIL appears to be comparable with originator filgrastim for mobilization purposes. 32, 35, 36 A retrospective analysis suggested that the combination of biosimilar FIL to plerixafor was not inferior when compared with the originator FIL plus plerixafor in hard-to-mobilize patients.
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A prolonged elimination half-life due to decreased serum clearance allows a single-dose administration of PEG. 5 Although PEG is indicated for the prophylaxis of febrile neutropenia after cytotoxic chemotherapy, the accumulating data on convenience, reliability, and effectiveness of PEG as a single dose of 6 mg in the mobilization of progenitor cells for transplant purposes are also available. 10, [14] [15] [16] 38 We have used PEG as a standard G-CSF both to mobilize progenitor cells as well as after infusion of blood grafts in lymphoma patients in the catchment area of Kuopio University Hospital since 2009. 17, 39 Differences in the number of hematopoietic progenitor cells as well as functional properties were observed in the PEG-mobilized apheresis products compared with FIL mobilized grafts.
12,40
In a gene expression study, 40 PEG-mobilized CD34 + cells had an excess of genes associated with early hematopoiesis as well as higher cell cycle activity. In our nonrandomized comparison, no significant differences were observed in the mobilization efficiency, although the number of CD34 + cells collected was lower in the PEG group compared with the FIL group. However, in the present study the tempo of engraftment after high-dose therapy was more rapid with PEG compared with FIL. The pharmacokinetic as well as pharmacodynamic properties are different in the novel pegylated G-CSF LIPEG compared with PEG due to differing site-specific glyco-pegylating technologies in their production. 20 Two randomized studies observed that the terminal elimination half-life of LIPEG was 5 to 10 hours longer compared with PEG in healthy subjects. 41 LIPEG had higher functional activity resulting from better resistance to human neutrophil elastase degradation compared with PEG. 42 A randomized phase III study showed LIPEG to be safe and noninferior to PEG regarding the length of neutropenia after chemotherapy. 43 LIPEG has significantly shortened the hospitalization time when administered after auto-SCT compared with FIL as well as reduced the number of platelet transfusions needed. 21 Our nonrandomized comparison suggests that LIPEG is superior in the mobilization of blood grafts for auto-SCT compared especially with PEG after chemotherapy in NHL patients. This was demonstrated by significantly higher B-CD34 + counts at the start of apheresis and significantly higher CD34 + cell yields of the first apheresis. Furthermore, the advantages of LIPEG use in the mobilization setting compared with FIL, despite similar total apheresis yields, include a single administration and lower laboratory costs as a consequence of fewer apheresis sessions that obviously compensates the lower costs of biosimilar filgrastim (Table 3 ). In addition, plerixafor, which may also reduce the time spent on apheresis, 44 was needed in only 13% of the patients in the LIPEG group. Further, early hematologic recovery appeared to be faster in the LIPEG group, and there was also a trend for a shorter hospitalization period during auto-SCT compared with the other groups, making this G-CSF appealing in the mobilization of CD34 + cells.
The most likely explanation for the faster hematopoietic recovery observed in the LIPEG group is the higher CD34 + cell counts in the grafts collected and subsequently infused, although there was no significant difference in the number of infused CD34 + cells between the LIPEG and FIL groups.
No differences were observed in the proportion or absolute number of more primitive CD34 + cells or immune cells in the grafts according to the G-CSF type used in the mobilization. The choice of G-CSF type was not due to the noninterventional GOA study but reflects local practices in the mobilization of CD34 + cells in the participating hospitals.
The limitations of our study are the small number of enrolled patients in the LIPEG group as well as the large variations in the mobilization regimens used. The smaller size of the LIPEG group compared with the other groups resulted from the later start of LIPEG use for mobilization purposes in the Kuopio University Hospital area. In regard to evaluation of neutrophil engraftment, variable use of G-CSF posttransplant may somewhat distort the results i.e. some patients in the PEG group received LIPEG after the graft infusion. However, the actual importance is supposed to be minimal, and no comparative studies have evaluated PEG versus LIPEG in the posttransplant phase. The patient population of the study groups was otherwise comparable, and the mobilization chemotherapies used were comparable between the pegylated G-CSF groups as well as the collection practices.
A review 45 and a more recent randomized study 46 concluded that the Spectra Optia has comparable apheresis yields with the Spectra-Auto, although collection efficiency was significantly higher in the Spectra Optia. Almost all the patients in our study were collected with the same apheresis system, further decreasing variation due to collection devices. Moreover, all B-CD34 + as well as LA-CD34 + measurements for LIPEG and PEG groups were performed at the same stem cell laboratory (Eastern Finland Laboratory Centre). Further, this prospective noninterventional multicenter study encompasses centrally analyzed graft composition by a single experienced flow cytometrist and the experience of a novel second-generation pegylated G-CSF LIPEG in progenitor cell mobilization including prospective evaluation of hematologic recovery after auto-SCT. To conclude, according to this prospective nonrandomized comparison, lipegfilgrastim appeared to be more efficient when added to chemotherapy to mobilize blood grafts for auto-SCT compared with pegfilgrastim or filgrastim and was associated with less cost. Based on these observations we have continued to use lipegfilgrastim in NHL patients also for mobilization purposes in our catchment area. A well-designed prospective randomized study comparing lipegfilgrastim with filgrastim for mobilization of CD34 + cells is warranted. 
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